MetLife Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

MetLife Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Buy	69,699 +25,829	+59%	+$115K	﹤0.01%	2088
2026 Q1	$165K	Buy	43,870 +18,273	+71%	+$61.7K	﹤0.01%	2322
2025 Q4	$77K	Sell	25,597 -9,720	-28%	-$24.6K	﹤0.01%	2673
2025 Q3	$67.1K	Sell	35,317 -21,027	-37%	-$36.7K	﹤0.01%	2769
2025 Q2	$80K	Buy	+56,344	New	+$76.2K	﹤0.01%	2644
2023 Q4	–	Sell	-35,160	Closed	-$241K	–	2825
2023 Q3	$241K	Hold	35,160	–	–	﹤0.01%	2094
2023 Q2	$365K	Buy	35,160 +1,261	+4%	+$11.4K	﹤0.01%	1899
2023 Q1	$274K	Hold	33,899	–	–	﹤0.01%	2024
2022 Q4	$534K	Buy	33,899 +2,628	+8%	+$42.3K	﹤0.01%	1603
2022 Q3	$492K	Hold	31,271	–	–	﹤0.01%	1644
2022 Q2	$437K	Buy	31,271 +4,989	+19%	+$69.9K	﹤0.01%	1762
2022 Q1	$453K	Buy	26,282 +9,700	+58%	+$132K	﹤0.01%	1835
2021 Q4	$241K	Hold	16,582	–	–	﹤0.01%	1944
2021 Q3	$298K	Hold	16,582	–	–	﹤0.01%	1825
2021 Q2	$291K	Buy	+16,582	New	+$377K	﹤0.01%	1914
2019 Q1	–	Sell	-13,157	Closed	-$97.2K	–	2569
2018 Q4	$97.2K	Hold	13,157	–	–	﹤0.01%	2305
2018 Q3	$191K	Hold	13,157	–	–	﹤0.01%	2111
2018 Q2	$263K	Buy	13,157 +3,244	+33%	+$59.9K	﹤0.01%	1782
2018 Q1	$174K	Hold	9,913	–	–	﹤0.01%	1955
2017 Q4	$244K	Buy	+9,913	New	+$241K	﹤0.01%	1824

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

MetLife Investment Management's ACRS Position: Q2 2026 in Review

MetLife Investment Management increased its Aclaris Therapeutics (ACRS) stake by 59% in Q2 2026, buying an estimated $115K and bringing the position to 69,699 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

MetLife Investment Management first reported a position in ACRS in Q4 2017 and has held it in 20 quarters since. The position peaked at $534K in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

MetLife Investment Management held 69,699 shares of Aclaris Therapeutics worth $369K as of Q2 2026.
MetLife Investment Management bought 25,829 Aclaris Therapeutics shares in Q2 2026, an estimated $115K.
Aclaris Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2088 holding.
MetLife Investment Management first reported a position in Aclaris Therapeutics in Q4 2017 and has held it in 20 quarters since.
MetLife Investment Management's Aclaris Therapeutics position peaked at $534K in Q4 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.